Newsroom

Blog

First CDx Approval for HLA Typing

We have seen HLA typing become more prominent in oncology clinical studies. Especially in the realm of immuno-oncology therapeutics including CAR T-cells, bi-specifics, and cancer vaccines.

Read More

Talking Cancer Blog: A Conversation with Holly Smithson, Athena CEO & Diversity Champion

Written By:
MadhuGhosh.jpg
Madhu Ghosh

ISO 15189 accreditation of the Swiss and Singapore NeoGenomics sites

In 2020 NeoGenomics decided to launch an accreditation program for its international sites in Switzerland and Singapore.

Read More
Written By:
Charlotte Serra profile image
Charlotte Serra

Entering the Multi-omics and precision medicine era in cancer research

Why multi-omics?
Read More
Written By:
QinqinZha.jpg
Qinqin Zha

The Story, The Patient, The Activist

We wanted to start 2022 by reinforcing NeoGenomics Laboratories, Inc.’s promise to work toward state-of-the-art diagnostic and oncology testing for patients.

Read More
Written By:
MadhuGhosh.jpg
Madhu Ghosh

Perspectives on a ssPMA CDx submission

The proprietary, high sensitivity Sanger sequencing assay (LOD <1%), developed by NeoGenomics, was used in certain BeiGene Phase 2 and Phase 3 clinical studies to determine the MYD88 status of p

Read More

Talking Cancer: Conversations with Trailblazers, Advocates, Patients, and Medical Ambassadors

In the middle of the pandemic, GO2 Foundation for Lung Cancer appointed Dr. Jennifer King as their Chief Scientific Officer in May 2020.

Read More
Written By:
MadhuGhosh.jpg
Madhu Ghosh

Enabling Precision Medicine for Breast Cancer Patients

Approximately every 2 minutes, a woman in the U.S. is diagnosed with breast cancer1. This high prevalence has led to rigorous standards of practice, from diagnosis to treatment.

Read More

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients